National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Benralizumab (Fasenra®)

Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

NCPE Assessment Process Complete
Rapid review commissioned 15/01/2018
Rapid review completed 14/02/2018
Rapid Review outcome Full pharamcoeconomic assessment recommended at the submitted price

The HSE has approved reimbursement following confidential price negotiations; April 2019